Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
- Conditions
- Squamous Cell Lung Cancer
- Interventions
- Drug: gemcitabine/carboplatin
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 780
- Registration Number
- NCT01082549
- Locations
- 🇺🇸
Investigational Site Number 840351, Muscle Shoals, Alabama, United States
🇺🇸Investigational Site Number 840338, Anaheim, California, United States
🇺🇸Investigational Site Number 840353, Burbank, California, United States
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT01082068
- Locations
- 🇺🇸
Investigational Site Number 5201, Columbia, Missouri, United States
🇺🇸Investigational Site Number 1537, Los Angeles, California, United States
🇺🇸Investigational Site Number 1138, Boston, Massachusetts, United States
Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT01081938
- Locations
- 🇧🇷
Sanofi-Aventis Investigational Site Number 076-007, Belo Horizonte, Brazil
🇧🇷Sanofi-Aventis Investigational Site Number 076-004, Porto Alegre, Brazil
🇧🇷Sanofi-Aventis Investigational Site Number 076-006, São José do Rio Preto, Brazil
Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 52
- Registration Number
- NCT01079364
- Locations
- 🇳🇱
Sanofi-Aventis Administrative Office, Gouda, Netherlands
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
- Conditions
- Acute Coronary Syndrome
- Interventions
- Drug: Placebo (for Otamixaban)Drug: Placebo (for UFH)Drug: UFHDrug: Placebo (for Eptifibatide)
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13220
- Registration Number
- NCT01076764
- Locations
- 🇺🇸
Investigational Site Number 840911, Pittsburgh, Pennsylvania, United States
🇦🇷Investigational Site Number 032010, Cordoba, Argentina
🇦🇷Investigational Site Number 032020, Mendoza, Argentina
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2011-02-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 82
- Registration Number
- NCT01076751
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Screening DIVA - Diffuse Vascular Disease
- Conditions
- Peripheral Vascular Diseases
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2233
- Registration Number
- NCT01076738
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada
Observatory on Elderly Patients "Les S.AGES"
- Conditions
- Chronic PainDiabetes Mellitus, Type 2Atrial Fibrillation
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3491
- Registration Number
- NCT01065909
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
- Conditions
- Dengue FeverDengue Hemorrhagic Fever
- Interventions
- Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virusBiological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccinesBiological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 210
- Registration Number
- NCT01064141
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2011-12-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3
- Registration Number
- NCT01063946
- Locations
- 🇧🇪
Sanofi-Aventis Administrative Office, Brussels, Belgium